Effective Date: 07/01/2024
Reviewed: 4/2024, 2/2025 Scope: Medicaid

Rexulti (brexpiprazole)

POLICY

I. INDICATIONS

Rexulti is indicated for:

- Adjunctive treatment of major depressive disorder (MDD) in adults.
- Treatment of schizophrenia in adults and pediatric patients ages 13 years and older
- Treatment of agitation associated with dementia due to Alzheimer's disease

Limitations of Use: Rexulti is not indicated as an as needed ("prn") treatment for agitation associated with dementia due to Alzheimer's disease

II. CRITERIA FOR APPROVAL

An authorization of 12 months may be granted when all the following criteria are met:

Schizophrenia

A. The member is being treated for schizophrenia; AND
B. The member has experienced a failure, contraindication, or intolerance to at least three formulary atypical antipsychotics (e.g., aripiprazole, olanzapine, quetiapine IR or ER, risperidone, or ziprasidone)

Major Depressive Disorder (MDD)

A. The member is being treated for adjunctive therapy for the treatment of MDD; AND
B. The member has experienced a failure, contraindication or intolerance to aripiprazole

Treatment of Agitation Associated with Dementia due to Alzheimer's Disease

A. The member is being treated for agitation associated with dementia due to Alzheimer's disease; AND
B. The member has experienced a failure, contraindication, or intolerance to at least one formulary selective serotonin reuptake inhibitor; AND
C. The member has experienced a failure, contraindication, or intolerance to at least one formulary generic atypical antipsychotic (e.g., aripiprazole, olanzapine, quetiapine IR or ER, risperidone, or ziprasidone)

III. CONTINUATION OF THERAPY

Rexulti will continue to pay after the initial approval if there is at least one paid claim of at least a 30-day supply within the last 365 days for Rexulti.

IV. QUANTITY LIMIT

Rexulti 0.25mg, 0.5mg, 1mg, 2mg, 3mg and 4mg tablets have a quantity limit of 1 tablet per day.

V. REFERENCES

1. Rexulti [prescribing information]. Rockville, MD: Otsuka America Pharmaceutical, Inc.; May 2023.